文献速递慢性肾脏病

三甲胺N-氧化物作为慢性肾脏病心血管并发症介质的作用

The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease.
PubMed 文献 · Kidney Int · 2017-08-12

综述探讨肠道来源的氧化三甲胺(TMAO)在慢性肾脏病(CKD)心血管疾病中的致病作用。CKD患者TMAO水平升高且经肾清除,实验研究提示TMAO通过脂代谢紊乱、巨噬细胞泡沫细胞形成和血小板功能障碍促进心血管病。益生菌等干预措施为介入研究提供机会。

要点

  • CKD患者血浆TMAO水平升高,肾脏清除减少。
  • TMAO可能通过脂代谢紊乱、泡沫细胞形成和血小板功能障碍促心血管病。
  • 益生菌等调节肠道菌群的干预为潜在治疗研究提供机会。

核心结论

  • TMAO在CKD患者中水平升高,可能作为心血管并发症的致病介质和治疗靶点。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • CKD患者TMAO水平升高且肾脏清除减少。
  • 实验研究显示TMAO通过脂代谢紊乱、巨噬细胞泡沫细胞形成和血小板功能障碍促进心血管病。

临床怎么用

  • TMAO可作为CKD心血管风险的生物标志物,调节肠道菌群(如益生菌)是潜在干预方向。

局限性

  • 综述未报告原始研究数据,TMAO的因果作用和干预获益尚需介入研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic kidney disease (CKD) have an enhanced risk of cardiovascular (CV) morbidity and mortality when compared with age- and gender-matched individuals with normal kidney function. Trimethlyamine N-oxide (TMAO) is a gut-derived amine oxide that has been implicated in the causation of CV diseases. Plasma TMAO is cleared by the kidney, and TMAO levels are elevated in CKD. Experimental studies have identified pathogenic mechanisms by which TMAO may contribute to CV disease through dysregulation of lipid metabolism, enhanced macrophage foam cell formation, and platelet dysfunction. Safe and well-tolerated therapeutic interventions such as pre- and probiotics, which modify the gut microbiome, offer the opportunity for interventional studies. This review examines the pathogenicity of TMAO, its value as a biomarker, and its potential as a therapeutic target in the context of CKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Tomlinson JAP, Wheeler DC. The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease. Kidney Int. 2017. PMID: 28807612. doi:10.1016/j.kint.2017.03.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。